Justice, Health Care & Enforcement
California Laboratory and Owner Agree to $1.25 Million Federal Settlement
The agreement resolves federal allegations that Lab Genomics and its owner paid volume-based commissions to marketers who generated laboratory-test referrals.
A civil resolution without a liability finding
Lab Genomics LLC and owner Leena Dalal agreed to pay $1.25 million to resolve federal allegations under the False Claims Act. The Justice Department says the Fountain Valley, California, laboratory paid improper commissions to independent marketers. The settlement resolves allegations only, and the department states that no determination of liability was made.
The alleged payment structure
According to the government's announcement, the disputed conduct ran from January 2020 through September 2022. Prosecutors alleged that commissions varied with the value and volume of referrals arranged or recommended by three independent contractors. The government also alleged that invoices were structured to make the payments appear to be flat fees. Those descriptions remain allegations resolved by agreement rather than trial findings.
Why referral payments receive scrutiny
The federal Anti-Kickback Statute restricts remuneration intended to induce referrals for items or services covered by federal health programs. Claims knowingly submitted in connection with prohibited payments can also create False Claims Act exposure. The legal question is not whether all marketing relationships are forbidden, but whether compensation and intent cross statutory lines. Providers need transaction-specific legal and compliance review.
The whistleblower component
The matter arose in part from a lawsuit filed under the False Claims Act's qui tam provisions, which allow private relators to bring claims on behalf of the United States. DOJ says the relators will receive $225,000 from the settlement proceeds. A relator share reflects the statutory process; it does not convert the settlement into a criminal conviction or establish every allegation in the complaint.
Records that matter next
The settlement agreement and federal court docket provide the operative terms, while later compliance or enforcement filings would show whether additional obligations arise. Laboratories and marketers should examine how compensation is calculated, documented and separated from referral volume. This report does not reproduce agency quotations or characterize the defendants as having admitted conduct that the government says was not adjudicated.
Primary evidence
Reporting note: This independently composed article is based on the linked primary records. Publication and event dates are stated separately. Agency claims are identified as such; an allegation, charge or scheduled event is not presented as a finding, conviction or completed event. Readers should consult the official record for amendments and later action.